Form 4: Dare Bioscience CEO Granted Stock Options
SEC Form 4 Filing
Dare Bioscience CEO, Sabrina Martucci Johnson, was granted 107,000 stock options on January 28, 2025, which vest over 48 months.
Summary
- Sabrina Martucci Johnson, CEO of Dare Bioscience, was granted 107,000 employee stock options on January 28, 2025.
- The options have an exercise price of $3.27 per share.
- The options vest in 48 equal monthly installments starting one month after the grant date, contingent on continuous service to the company.
- The options expire on January 28, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The granting of stock options to the CEO aligns her interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the options is dependent on the future performance of Dare Bioscience's stock price.
- If the CEO leaves the company before the options fully vest, she may forfeit some or all of the options.
Future Outlook
The stock options will vest over the next 48 months, subject to the CEO's continued employment.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech industry.
- The vesting schedule of 48 months is typical for such grants, encouraging long-term commitment.
- The exercise price of $3.27 is specific to Dare Bioscience's stock and market conditions at the time of the grant.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/28/2025 | Date of the stock option grant. |
| 01/31/2025 | Date of the filing of the SEC Form 4. |
| 01/28/2035 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, insider trading, Dare Bioscience, CEO, Sabrina Martucci Johnson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.